U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H18BrN3O2
Molecular Weight 436.301
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LY-288513

SMILES

BrC1=CC=C(NC(=O)N2NC(=O)[C@H]([C@@H]2C3=CC=CC=C3)C4=CC=CC=C4)C=C1

InChI

InChIKey=LMUQHXHWJWQXSD-PMACEKPBSA-N
InChI=1S/C22H18BrN3O2/c23-17-11-13-18(14-12-17)24-22(28)26-20(16-9-5-2-6-10-16)19(21(27)25-26)15-7-3-1-4-8-15/h1-14,19-20H,(H,24,28)(H,25,27)/t19-,20-/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H18BrN3O2
Molecular Weight 436.301
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

LY-288513 is a selective CCK2 receptor antagonist (IC50 values are 16 and > 30,000 nM for CCK2 and CCK1 respectively). LY-288513 displays anxiolytic and antipsychotic properties in vivo.

CNS Activity

CNS Active
3913
Curator's Comment: In the elevated plus-maze, LY-288513 (3, 10 mg/kg, IP; 10, 30 mg/kg, PO) produced an anxiolytic-like action in mice with a magnitude of effect similar to that of diazepam.

Originator

Eli Lilly
237
Curator's Comment: # Eli Lilly

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 7.03 null [pIC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

5399708
1

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Subcutaneous administration of LY-288513 30 min before footshock (0.3 mg/kg) and 30 min before conditioned fear stress (0.03 mg/kg) reduced conditioned freezing in rats. https://www.ncbi.nlm.nih.gov/pubmed/8741161
Mice: In the elevated plus-maze, LY-288513 (3, 10 mg/kg, IP; 10, 30 mg/kg, PO) produced an anxiolytic-like action in mice with a magnitude of effect similar to that of diazepam. High doses of LY288513 (1000 mg/kg, PO) were required to reduce spontaneous activity levels, decrease body temperature, or potentiate the CNS-depressant effects of hexobarbital.
Route of Administration: Other
In Vitro Use Guide
LY-288513 (10(−8) mol/l) reduced the suppressive effects of CCK-8 on mouse CD4(+) T cell subset-specific transcription factors (T-bet and RORγt mRNA), and the stimulatory effects on GATA3 and Foxp3.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:40:24 GMT 2023
Edited
by admin
on Fri Dec 15 15:40:24 GMT 2023
Record UNII
470GWP2CA0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LY-288513
Common Name English
1-PYRAZOLIDINECARBOXAMIDE, N-(4-BROMOPHENYL)-3-OXO-4,5-DIPHENYL-, (4S,5R)-
Systematic Name English
Code System Code Type Description
CAS
147523-65-7
Created by admin on Fri Dec 15 15:40:24 GMT 2023 , Edited by admin on Fri Dec 15 15:40:24 GMT 2023
PRIMARY
PUBCHEM
2802894
Created by admin on Fri Dec 15 15:40:24 GMT 2023 , Edited by admin on Fri Dec 15 15:40:24 GMT 2023
PRIMARY
FDA UNII
470GWP2CA0
Created by admin on Fri Dec 15 15:40:24 GMT 2023 , Edited by admin on Fri Dec 15 15:40:24 GMT 2023
PRIMARY
Related Record Type Details
Structure of LY-288513
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966